Relmada Therapeutics Joins Russell 2000 and 3000 Indices, Boosting Stock Prospects

Key Facts

In a move that enhances the stock's market presence, Relmada Therapeutics has been added to the Russell 2000 and Russell 3000 indices as part of the annual reconstitution. According to reports, the inclusion was based on market capitalization criteria. Such index additions typically trigger passive fund inflows, providing a potential boost to the stock.

RLMD closed at $6.69 on June 26, 2026, near the low end of its weekly range between $6.40 and $6.95. The inclusion is expected to attract flows from passive funds tracking the Russell 2000, potentially supporting the stock in the near term. Relmada is a clinical-stage biotech firm, making the index addition a notable milestone for investor visibility.

At the current close of $6.69, the stock trades near the lower end of its weekly range. Investors will focus on Relmada's clinical trial results, as the index inclusion does not alter the company's fundamentals. The stock's key catalysts remain tied to its drug pipeline developments and upcoming clinical milestones.